Asset Details
Do you wish to reserve the book?
Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
Do you wish to request the book?
Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
2026
Overview
Chronic graft versus host disease (cGVHD) affects 30–50% of allogeneic hematopoietic stem cell transplantation recipients, with those failing standard therapy including ruxolitinib constituting an important unmet medical need. We retrospectively analyzed the use of the ROCK2 inhibitor belumosudil in moderate to severe cGVHD that had failed ≥ 2 lines of systemic therapies, in order to evaluate its efficacy and safety in routine practice. Eighteen men and thirteen women at a median age of 50 (21–68) years with cGVHD (moderate,
N
= 12; severe,
N
= 19) that had failed a median of 3 (2–6) lines of systemic therapy were studied. Twenty-eight patients (90%) had failed prior ruxolitinib therapy, with seventeen patients (55%) continuing ruxolitinib despite unsatisfactory response. Among 29 patients evaluable, overall response rate was 52% (complete response:7%; partial response: 45%). Median time to response was 2.1 months (95% confidence interval, CI: 1.6–5.7), and was significantly shorter in patients older than 50 years (
P
= 0.008) and having received < 4 lines of therapy (
P
= 0.007). Median duration of response was 36.8 weeks (95% CI: 16.4 weeks to not reached). Median time to reduction of immunosuppressants by ≥ 50% was 6.7 months (95% CI: 2.3–12.2). Grade ≥ 3 adverse events occurred in 13% (4/31) of patients. Six patients (19%) discontinued treatment. At 12 months, overall survival and failure-free survival were 95% and 55%. Concomitant ruxolitinib significantly increased the probability of immunosuppressant reduction (
P
= 0.007). Belumosudil showed promising efficacy and safety in cGVHD patients in routine practice.
